Day 4 Recap: Maui Derm NP+PA Fall 2024
Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.
Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.
The subsequent MAD portion of the study has commenced dosing. Results are anticipated in Q4.
The Adbry 300 mg/2 mL autoinjector reduces the number of self injections required for patients, who currently have a 150mg/1mL pre-filled syringe available.
This case-control study examines the association of precocious puberty with hidradenitis suppurativa among US children and adolescents.
Researchers authored a manuscript detailing considerations for GPP diagnosis, definitions, and management.
Precision measurements are necessary to improve the current therapeutic armamentarium in pigmentary disorders.
Saturday, October 26, 2024 6:15 am – 7:15 am ET Sheraton Boston Hotel | Boston, Massachusetts In-Person Food allergies affect both children and adults. They…
Five experts delve into the multifaceted aspects of pediatric atopic dermatitis care including demographic variances to long-term safety and efficacy, comparative analyses, key takeaways from…
Hilary Baldwin, MD, emphasized involving patients in the decision-making process to create a personalized and cost-effective plan.
One of the joys of dermatology is that there is rarely a dull moment.
In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical…